NVE Corporation 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2006 (the first quarter of fiscal 2007). NVE Corporation develops, manufactures, and sells "spintronics" devices, a nanotechnology utilizing electron spin for data acquisition, storage, and transmission. The company also licenses MRAM technology and manufactures high-performance sensors and couplers.
Key Financial Metrics
| Metric | Q1 2007 (Ended June 30, 2006) | Q1 2006 (Ended June 30, 2005) |
|---|---|---|
| Total Revenue | $3,635,195 | $3,025,548 |
| Gross Profit | $2,235,374 | $1,344,430 |
| Gross Margin | 61.5% | 44.4% |
| Net Income | $891,806 | $412,649 |
| Diluted EPS | $0.19 | $0.09 |
| Operating Cash Flow | $591,598 | $714,684 |
| Cash & Investments | $11,789,206 | $10,891,326 (Mar 31, 2006) |
| Debt | $0 | $33,281 (Capital Lease) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20.1% year-over-year. This was driven by a 71.1% surge in product sales ($3.05M vs $1.78M), partially offset by a 53.1% decline in contract research and development revenue ($582k vs $1.24M) due to a strategic shift toward company-funded research and reduced government contract awards.
- Margin Expansion: Gross profit margin improved significantly to 61.5% from 44.4%, attributed to a more profitable revenue mix, price increases implemented in calendar 2006, and lower-cost coupler designs.
- Profitability: Net income more than doubled (116.1% increase) to $891,806, fueled by higher revenue and gross profit despite a 41% increase in R&D expenses.
- Debt Elimination: The company retired all capital lease obligations ($33,281) during the quarter, leaving the balance sheet debt-free.
Outlook, Risks, and Management Commentary
- Guidance: Management expects product revenue to increase for the remainder of fiscal 2007 due to new coupler/sensor sales, growth in the medical device market, and prior price increases. Conversely, contract R&D revenue is expected to decrease further as the company shifts focus to internal product development.
- Expense Outlook: R&D expenses are expected to rise due to new product development. SG&A expenses may increase due to legal costs or potential MRAM license acquisitions.
- Liquidity: The company holds approximately $11.8 million in cash and investments, deemed adequate for the next 12 months. Capital expenditures of $57,254 were made for production capacity, with $90,000 in commitments remaining.
- Risks & Contingencies: The company is defending against a class-action lawsuit filed in February 2006 alleging securities violations regarding projected revenues and technology. Management believes the suits are without merit and has not recorded a liability, though legal expenses are expected to continue. There are no material changes to risk factors from the prior 10-K.
- Accounting Changes: The company adopted SFAS No. 123(R) effective April 1, 2006, for stock-based compensation. The impact on EPS for the quarter was less than $0.01.
Investor Verification Checklist
- Sustainability of Product Sales: Verify the durability of the 71% increase in product sales and the success of the shift away from government contract revenue.
- Legal Exposure: Monitor the status of the securities class-action lawsuit and associated legal expense accruals.
- Margin Maintenance: Confirm that gross margins remain elevated as the revenue mix shifts and new products are introduced.
- Investment Portfolio: Review the composition of the $10M+ investment portfolio (53% of total assets) for interest rate sensitivity and unrealized gains/losses.